IMab (IMAB)
(Delayed Data from NSDQ)
$3.37 USD
+0.44 (15.02%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $3.30 -0.07 (-2.08%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
I-Mab Sponsored ADR's dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
IMAB 3.37 +0.44(15.02%)
Will IMAB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IMAB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMAB
I-Mab Sponsored ADR (IMAB)'s Technical Outlook is Bright After Key Golden Cross
I-Mab Sponsored ADR (IMAB) is a Great Momentum Stock: Should You Buy?
IMAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
After Plunging -20.33% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB)
After Plunging -19.7% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB)
IMab (IMAB) Moves to Buy: Rationale Behind the Upgrade
Other News for IMAB
12 Health Care Stocks Moving In Friday's Intraday Session
I-Mab (IMAB) Gains Strategic Investment from Everest Medicines
I-Mab (IMAB) Announces Pricing for ADS Offering
Everest Medicines Expands Strategic Investment in I-MAB | IMAB Stock News
Everest Medicines announces strategic equity investment in I-Mab